TWEAK and NT-proBNP levels predict exercise capacity in hypertrophic cardiomyopathy
Autors de IIS La Fe
Autors aliens a IIS La Fe
- Hernández-Romero D
- Jover E
- Martínez CM
- Andreu-Cayuelas JM
- Orenes-Piñero E
- Romero-Aniorte AI
- Casas T
- Cánovas S
- Valdés M
- de la Morena G
Grups d'Investigació
Abstract
BackgroundHypertrophic cardiomyopathy (HCM) is characterized by inappropriate hypertrophy, myocyte disarray and increased interstitial fibrosis. The tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a cell surface cytokine with biological activities including stimulation of cell growth, induction of inflammatory cytokines and stimulation of apoptosis. There are controversial data about the potential role of TWEAK in different cardiovascular pathologies. NT-proBNP is an established biomarker of myocardial wall stress, associated with poor functional class in HCM. We hypothesized that effort capacity in patients with HCM could be related to serum levels of these biomarkers. Materials and methodsWe included 40 haemodynamic stable HCM patients and 53 healthy controls with similar sex and age. We studied exercise capacity by maximal oxygen consumption in a limited treadmill exercise test. TWEAK and NT-proBNP were assayed by ELISA method and automated Elecsys (R) platform, respectively. We obtained 46 samples of myocardial tissues by septal myectomy in patients with HCM and evaluated myocardial fibrosis, immunoreaction with TWEAK antibody and apoptosis with TUNEL assay. ResultsWe found raised TWEAK and NT-proBNP serum levels in patients when compared with control levels (both P<0001). In a multivariate analysis, TWEAK and NT-proBNP levels, as well as sex, remained independently associated with the effort capacity (all P<005). We found an association between immunoreaction degree and the degree of myocardial fibrosis (P=0021), as well as apoptosis (P=0002) in the tissue samples from patients undergoing septal myectomy. ConclusionsTWEAK and NT-proBNP levels are biomarkers of disease severity independently associated with the effort capacity in patients with HCM.
Dades de la publicació
- ISSN/ISSNe:
- 0014-2972, 1365-2362
- Tipus:
- Article
- Pàgines:
- 179-186
- DOI:
- 10.1111/eci.12394
- PubMed:
- 25524713
- Factor d'Impacte:
- 1,232 SCImago ℠
- Quartil:
- Q1 SCImago ℠
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION WILEY
Cites Rebudes en Web of Science: 4
Documents
- No hi ha documents
Filiacions
Keywords
- Effort capacity; hypertrophic cardiomyopathy; myocardial fibrosis; NT-proBNP; TWEAK
Projectes associats
REDINSCOR
RD06/0003/1001 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2008
RED DE BIOBANCOS (BIOBANCOS)
RD09/0076/00021 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010
REGISTRO MULTICÉNTRICO DE PACIENTES HOSPITALIZADOS POR INSUFICIENCIA CARDÍACA AGUDA (REDINSCOR II).
RD12/0042/0003 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013
RED DE TERAPIA CELULAR (TERCEL)
Investigador Principal: PILAR SEPÚLVEDA SANCHIS
RD12/0019/0025 . INSTITUTO DE SALUD CARLOS III; FUNDACION FORMACION E INVESTIGACIÓN SANITARIA MURCIA (IMIB); FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013
HECATOS. HEPATIC AND CARDIAC TOXICITY SYSTEMS MODELLING.
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
602156_HECATOS_PE_FP7-HEALTH-2013-INNOVATI . 2013
MECANISMOS MOLECULARES Y CELULARES DE LAS CELULAS MESENQUIMALES HUMANAS Y DE LAS CELULAS CARDIACAS RESIDENTES DEL ADULTO EN EL ENTORNO CARDIACO ISQUEMICO Y EL NICHO HEMATOPOYETICO.
Investigador Principal: PILAR SEPÚLVEDA SANCHIS
PI13/00414 . INSTITUTO DE SALUD CARLOS III . 2014
DESARROLLO Y VALIDACIÓN DE UN MODELO DE ISQUEMIA MIOCÁRDICA PRECOZ MEDIANTE ESPECTROMETRÍA DE MASAS.
Investigador Principal: BEGOÑA IGUAL MUÑOZ
APM-39/15 . 2015
ESTUDIO DE DURABILIDAD DEL TRIFECTA.
Investigador Principal: JOSÉ ANASTASIO MONTERO ARGUDO
CS-10-012-EU-TV . 2011
ESTUDIO DE LA TOXICIDAD EN PLASMA INDUCIDA POR AGENTES QUIMIOTERÁPICOS.
Investigador Principal: JOSÉ ANASTASIO MONTERO ARGUDO
CARDIOTOX CLÍNICO